Latest:
Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer
Studies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Francis J. Giles, MD
Latest:
ASH Interview Series
The December issue of Oncology & Biotech News featured highlights from the 51st American Society of Hematology (ASH) Annual Meeting and Exposition. We wrap up our ASH coverage this month with interviews on multiple myeloma with Brian G.M. Durie, MD, medical director and co-founder of the International Myeloma Foundation; chronic lymphocytic leukemia (CLL) with Robert J. Kreitman, MD, from the National Cancer Institute; and chronic myeloid leukemia (CML) with Francis J. Giles, MD, Cancer Therapy and Research Center at The University of Texas Health Science Center in San Antonio.
Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center
Latest:
Emerging Phase 3 Trial: Pembrolizumab Plus PDS0101 (HPV-16 Targeted Cancer Vaccine) in HPV-Positive HNSCC (VERSATILE-003)
Panelists discuss the priority next steps for PDS0101 plus pembrolizumab in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): expand clinical trials, identify predictive biomarkers, assess long-term safety, and explore additional combination approaches.
Francis Yao, MD
Latest:
Dr. Yao on Transplants Beyond Milan Criteria for Liver Cancer
Francis Yao, MD, gastroenterologist and medical director of the Liver Transplant Program at the University of California San Francisco Medical Center, discusses liver transplants beyond Milan criteria for patients with liver cancer.
Francisco Esteva, MD, PhD
Latest:
Dr Esteva on the Impact of the MAINTAIN Trial in HR+/HER2– Breast Cancer
Francisco J. Esteva, MD, PhD, discusses the impact of the phase 2 MAINTAIN study of treatment with ribociclib following progression on CDK4/6 inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.
Francois-Clement Bidard, MD, PhD
Latest:
Dr. Bidard on the FDA Approval of Elacestrant in ER+/HER2– Metastatic Breast Cancer
François-Clément Bidard, MD PhD, discusses the significance of the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer and key efficacy and safety data from the phase 3 EMERALD trial.
Francoise Horand
Latest:
Erythrocytes Used as Tumor Antigen Delivery System
Françoise Horand, director, R&D Operations, Erytech Pharma, discusses a study investigating the use of erythrocytes as a tumor antigen delivery system to target antigen-presenting cells and induce efficient immune response against tumors.
Frank A. Sinicrope, MD
Latest:
Dr. Sinicrope on Mismatch Repair-Deficient Patients With Metastatic Colorectal Cancer
Frank A. Sinicrope, MD, medical oncologist, Departments of Gastroenterology and Hepatology and Oncology, Mayo Clinic, discusses patients with metastatic colorectal cancer (mCRC) who are mismatch repair-deficient.
Frank A. Vicini, MD
Latest:
Dr. Vicini on the Potential Utility of the DCISionRT Test in HER2+ DCIS of the Breast
Frank A. Vicini, MD, discusses the potential utility of using the DCISionRT test to determine treatment benefit in the phase 3 NRG-NSABP-B43 trial in HER2-positive ductal carcinoma in situ of the breast.
Frank E. Mott, MD
Latest:
Dr. Mott on Sequencing of Treatments with NSCLC
Frank E. Mott, MD, associate professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the sequencing of treatments for patients with non-small cell lung cancer (NSCLC).